Volume 34, No 6, Jun 2024

ISSN: 1001-0602 
EISSN: 1748-7838 2018 
impact factor 17.848* 
(Clarivate Analytics, 2019)

Volume 34 Issue 6, June 2024: 403-404

RESEARCH HIGHLIGHTS

Cytolytic too: Granzyme B-expressing human ILC2s mediate tumor rejection

Hergen Spits^1,* , Jenny Mjösberg^2,3

¹Department of Experimental Immunology of Amsterdam UMC, Amsterdam Institute for Immunology and Infectious Diseases, Cancer Center Amsterdam, Amsterdam, The Netherlands
²Center for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
³Clinical Lung and Allergy Research Unit, Department of Medicine Huddinge, Karolinska Institutet, Medical unit for Lung and Allergy Diseases, Karolinska University Hospital Huddinge, Stockholm, Sweden
Correspondence: Hergen Spits(Hergen.spits@amsterdamumc.nl)

Group 2 innate lymphoid cells (ILC2s), known for their role in defending against parasites and regulating tissue homeostasis through cytokine secretion, were found to have a new function. Research in Cell shows that, when cultivated in a lab, human ILC2s can target and destroy tumor cells in a living organism using various cell death mechanisms.

https://doi.org/10.1038/s41422-024-00937-0

FULL TEXT | PDF

Browse 555